Nexstim, Oy: Series D $2.8M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Device (Imaging), X - Device (Neuromod)

Nexstim (Finland) a commercial-stage developer of non-invasive brain imaging technologies focused on cortical mapping prior to surgery, closed a $2.8M Series D financing, bringing the total round to $19.2M. Participants include Capricorn Health-tech Fund, Tekes, HealthCap, Sitra, Finnish Industry Investment, Lundbeckfond Ventures and Ilmarinen.

Curexo Technology Corp.: Series C $13.2M

Posted in I - Series C, Q - 2Q10, R - INTERNATIONAL, X - Device (Orthopedic)

Curexo Technology (Korea) a commercial-stage medical device company focused on robotic surgical systems for joint replacement, closed a $13.2M Series C financing. Participants were not identified.

Ensysce Biosciences, Inc.: Series A $1.5M

Posted in I - Series A, Q - 2Q10, R - SOUTH WEST, X - Device (Delivery), XX - TX

Ensysce Biosciences (Houston, TX) a development-stage biopharma company focused on carbon nanotube complexes for chemotherapeutic transport, closed a $1.5M Series A financing. Participants include Texas Emerging Technology Fund.

Green Biologics, Ltd.: Series B $6.1M

Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Biofuel

Green Biologics (United Kingdom) a development-stage biotechnology fermentation company focused on bio-butanol for biochemicals and biofuels, closed a $6.1M Series B financing. Participants include Capricorn Venture Partners, Morningside Ventures, Carbon Trust Investment Limited and Oxford Capital Partners.

Zymeworks, Inc.: Series B $3.2M

Posted in I - Series B, Q - 2Q10, R - INTERNATIONAL, X - Bioinformatics

Zymeworks (Canada) a development-stage bioinformatics company focused on in silico optimization of protein-based therapeutics, closed a $3.2M Series B financing. Participants include CTI Life Sciences Fund.

Molecular Detection, Inc.: Series C $1.4M

Posted in I - Series C, Q - 2Q10, R - NORTH EAST, X - Device (Diagnostic), X - MRSA, XX - PA

Molecular Detection (Wayne, PA) a commercial-stage molecular diagnostics company focused on MRSA detection, closed a $1.4M Series C financing, bringing the total round to $4.7M. Participants include MentorTech Ventures.

Zeltiq, Inc.: Series D $25M

Posted in I - Series D, Q - 2Q10, R - WEST, X - Device (Lypolysis)

Zeltiq (Pleasanton, CA) a commercial-stage medical device company focused on lipolysis for fat reduction and other dermatological applications, closed a $25M Series D financing. Participants include Aisling Capital, Venrock, Frazier Healthcare Ventures and Advanced Technology Ventures.

NanoPowers, SA: Series A $4.5M

Posted in I - Series A, Q - 2Q10, R - INTERNATIONAL, X - Device (Urology)

NanoPowers (Switzerland) a development-stage medical device company focused on urinary incontinence, closed a $4.5M Series A financing. Participants include Novartis Venture Funds, Initiative Capital Romandie and Gran Plasa.

SynapDx Corp.: Series A $9M

Posted in I - Series A, Q - 2Q10, R - NORTH EAST, X - Autism, X - Device (Diagnostic), XX - MA

SynapDx (Waltham, MA) a development-stage diagnostic company focused on the early detection of autism, closed a $9M Series A financing. Participants include Bain Capital Ventures, General Catalyst Partners and North Bridge Venture Partners.

Reinnervate, Ltd.: Series A $2M

Posted in I - Series A, Q - 2Q10, R - INTERNATIONAL, X - Cell Culture

Reinnervate (United Kingdom) a development-stage company focused on in vitro cell culture technologies, closed a $2M Series A financing. Participants include NorthStar Equity Investors.

Noxxon Pharma, AG: Series D $40M

Posted in I - Series D, Q - 2Q10, R - INTERNATIONAL, X - Aptamer, X - Hematology, X - Inflammation

Noxxon Pharma (Germany) a clinical-stage biopharmaceutical company focused on the development of aptamers for the treatment of inflammation and hematological indications closed a $40M Series D financing. Participants include NGN Capital, TVM Capital, Sofinnova Partners, Edmond de Rothschild Investment Partners, Seventure Partners, VC Fonds Technologie Berlin, Dow Venture Capital, Fcp Medical BioHealth-Trends, IBG Beteiligungsgesellschaft Sachsen-Anhalt [...]

Phreesia, Inc.: Series D $16M

Posted in I - Series D, Q - 2Q10, R - NORTH EAST, X - Bioinformatics, X - TeleMedicine, XX - NY

Phreesia (New York, NY) a commercial-stage developer of patient intake data, closed a $16M Series D financing. Participants include Ascension Health Ventures, BlueCross BlueShield Venture Partners, Sandbox Industries, Polaris Venture Partners, HLM Venture Partners and Long River Ventures.

Palmaz Scientific, Inc.: Series A $3M

Posted in I - Series A, Q - 2Q10, R - SOUTH WEST, X - Biomaterial, XX - TX

Palmaz Scientific (Dallas, TX) a development-stage nano-biomaterials company focused on a vapor deposition process to increase the reliability of implantable prosthetic devices, closed a $3M Series A financing. Participants include Texas Emerging Technology Fund.

« Previous Entries

to top of page...